Literature DB >> 28116650

The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis.

Michael Brendan Cloney1, Adam M Sonabend2, Jonathan Yun1, Jingyan Yang3, Fabio Iwamoto4, Suprit Singh1, Govind Bhagat5, Peter Canoll5, George Zanazzi5, Jeffrey N Bruce1, Michael Sisti1, Sameer Sheth1, E Sander Connolly1, Guy McKhann1.   

Abstract

Surgical resection is not the standard of care for primary central nervous system lymphoma (PCNSL), as historical studies have demonstrated unfavorable complication rates and limited benefits. Some recent studies suggest that resection may provide a therapeutic benefit, yet the safety of these procedures has not been systematically investigated in the setting of modern neurosurgery. We examined the safety of surgical resection for PCNSL. We retrospectively analyzed all patients with PCNSL treated at Columbia University Medical Center between 2000 and 2015 to assess complications rates following biopsy or resection using the Glioma Outcomes Project system. We identified predictors of complications and selection for resection. Well-validated scales were used to quantify patients' baseline clinical characteristics, including functional status, comorbid disease burden, and cardiac risk. The overall complication rate was 17.2% after resection, and 28.2% after biopsy. Cardiac risk (p = 0.047, OR 1.72 [1.01, 2.95]), and comorbid diagnoses (p = 0.004, OR 3.05 [1.42, 6.57]) predicted complications on multivariable regression. Patients who underwent resection had better KPS scores (median 70 v. 80, p = 0.0068, ∆ 10 [0.0, 10.00]), and were less likely to have multiple (46.5% v. 27.6%, p = 0.030, OR 1.42 [1.05, 1.92]) or deep lesions (70.4% v. 39.7%, p = 0.001, OR 1.83 [1.26, 2.65]). Age (p = 0.048, OR 0.75 per 10-year increase [0.56, 1.00]) and deep lesions (p = 0.003, OR 0.29 [0.13, 0.65]) influenced selection for resection on multivariable regression. Surgical resection of PCNSL is safe for select patients, with complication rates comparable to rates for other intracranial neoplasms. Whether there is a clinical benefit to resection cannot be concluded.

Entities:  

Keywords:  CNS lymphoma; Central nervous system lymphoma; Complications; PCNSL; Resection

Mesh:

Year:  2017        PMID: 28116650      PMCID: PMC5367383          DOI: 10.1007/s11060-016-2358-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  45 in total

1.  Surgery for primary CNS lymphoma? Challenging a paradigm.

Authors:  Michael Weller; Peter Martus; Patrick Roth; Eckhard Thiel; Agnieszka Korfel
Journal:  Neuro Oncol       Date:  2012-09-14       Impact factor: 12.300

2.  Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma.

Authors:  I F Pollack; L D Lunsford; J C Flickinger; H L Dameshek
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

3.  Primary malignant lymphomas of the central nervous system.

Authors:  J M Henry; R R Heffner; S H Dillard; K M Earle; R L Davis
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

4.  The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma.

Authors:  Randy S D'Amico; Michael B Cloney; Adam M Sonabend; Brad Zacharia; Matthew N Nazarian; Fabio M Iwamoto; Michael B Sisti; Jeffrey N Bruce; Guy M McKhann
Journal:  World Neurosurg       Date:  2015-06-11       Impact factor: 2.104

5.  Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care.

Authors:  Fred G Barker; William T Curry; Bob S Carter
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

6.  Surgical outcomes in recurrent glioma: clinical article.

Authors:  Jason M Hoover; Macaulay Nwojo; Ross Puffer; Jay Mandrekar; Fredric B Meyer; Ian F Parney
Journal:  J Neurosurg       Date:  2013-03-15       Impact factor: 5.115

7.  Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study.

Authors:  Adam M Sonabend; Brad E Zacharia; Michael B Cloney; Aarón Sonabend; Christopher Showers; Victoria Ebiana; Matthew Nazarian; Kristin R Swanson; Anne Baldock; Henry Brem; Jeffrey N Bruce; William Butler; Daniel P Cahill; Bob Carter; Daniel A Orringer; David W Roberts; Oren Sagher; Nader Sanai; Theodore H Schwartz; Daniel L Silbergeld; Michael B Sisti; Reid C Thompson; Allen E Waziri; Zoher Ghogawala; Guy McKhann
Journal:  Neurosurgery       Date:  2017-04-01       Impact factor: 4.654

8.  Primary lymphoma of the central nervous system. Clinicopathological study of experience at Stanford.

Authors:  T L Helle; R H Britt; T V Colby
Journal:  J Neurosurg       Date:  1984-01       Impact factor: 5.115

Review 9.  Primary central nervous system lymphoma.

Authors:  F H Hochberg; D C Miller
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

10.  Primary intracranial lymphomas.

Authors:  G Frank; R Ferracini; F Spagnolli; F Frank; G Gaist; P Lorenzini; R Ricci
Journal:  Surg Neurol       Date:  1985-01
View more
  9 in total

1.  Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI.

Authors:  Fu-Hua Lin; Xiang-Heng Zhang; Ji Zhang; Zhen-Qiang He; Hao Duan; Chao Ke; Ke Sai; Xiao-Bing Jiang; Fuad Al-Nahari; Shao-Yan Xi; Yong-Gao Mou
Journal:  J Neurooncol       Date:  2018-08-16       Impact factor: 4.130

2.  Craniotomy and Survival for Primary Central Nervous System Lymphoma.

Authors:  Ali I Rae; Amol Mehta; Michael Cloney; Connor J Kinslow; Tony J C Wang; Govind Bhagat; Peter D Canoll; George J Zanazzi; Michael B Sisti; Sameer A Sheth; E Sander Connolly; Guy M McKhann; Jeffrey N Bruce; Fabio M Iwamoto; Adam M Sonabend
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

3.  Primary Brainstem Lymphoma: A Population-Based Study.

Authors:  Junyu Chen; Bo Cen; Fei Hu; Yong Qiu; Guomin Xiao; Junge Zhou; Xiujian Ma; Fangcheng Zhang
Journal:  Front Surg       Date:  2022-07-06

Review 4.  The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.

Authors:  Lisette M Vernooij; Wilton A van Klei; Karel Gm Moons; Toshihiko Takada; Judith van Waes; Johanna Aag Damen
Journal:  Cochrane Database Syst Rev       Date:  2021-12-21

5.  The role of surgery in intracranial PCNSL.

Authors:  Guro Jahr; Michele Da Broi; Harald Holte; Klaus Beiske; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2018-01-27       Impact factor: 3.042

6.  The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients.

Authors:  Shiqiang Wu; Junwen Wang; Weihua Liu; Feng Hu; Kai Zhao; Wei Jiang; Ting Lei; Kai Shu
Journal:  BMC Neurol       Date:  2021-05-11       Impact factor: 2.474

Review 7.  An Update on Neurosurgical Management of Primary CNS Lymphoma in Immunocompetent Patients.

Authors:  Florian Scheichel; Daniel Pinggera; Branko Popadic; Camillo Sherif; Franz Marhold; Christian Franz Freyschlag
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

8.  Clinical Impact of the Histopathological Index and Neuroimaging Features Status in Primary Central Nervous System Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Analysis of 51 Cases.

Authors:  Zhou Qi; Lei Duan; Guoqiang Yuan; Jianli Liu; Jian Li; Guoqiang Li; Yue Yu; Yanlong Xu; Shangxian Ma; Yawen Pan; Yinian Zhang
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

9.  Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study.

Authors:  Tianwang Guan; Zicong Qiu; Miao Su; Jinming Yang; Yongshi Tang; Yanting Jiang; Dunchen Yao; Yanxian Lai; Yanfang Li; Cheng Liu
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.